Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2018 Oct;18(sup1):13-17. doi: 10.1080/14737140.2018.1513792.

Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.

Author information

1
a European Institute of Oncology , University of Milan-Bicocca , Milan , Italy.

Abstract

OBJECTIVES:

Ovarian cancer patients with relapse 6-12 months after last platinum treatment, who have received bevacizumab consolidation and are not BRCA mutant, represent a considerable therapeutic challenge.

METHODS:

By means of illustrative case study, this review evaluates various treatment strategies for use at first relapse in an ovarian cancer patient with limited sensitivity to platinum.

RESULTS:

Clinical parameters predictive of complete resection in secondary cytoreductive surgery include an Eastern Cooperative Oncology Group performance status of 0, no residual disease after first surgery, and <500 mL of ascites. Options for systemic therapy include platinum-based therapies, non-platinum combinations, and non-platinum single agents. The patient's circumstances suggested that the non-platinum combination of trabectedin + pegylated liposomal doxorubicin (PLD) would be most appropriate. Trabectedin + PLD may enhance response to the next platinum cycle and thus prolong survival although this hypothesis requires confirmation. At minimum, trabectedin + PLD provides additional time for patients to recover from previous platinum toxicity while receiving an effective treatment.

CONCLUSION:

In recurrent ovarian cancer patients with expected suboptimal response to platinum, trabectedin + PLD may offer an active alternative, which differs from the first-line schedule, and may enhance the efficacy of subsequent platinum rechallenge.

KEYWORDS:

Recurrent ovarian cancer; non-platinum combinations; sequence effect; trabectedin

PMID:
30223694
DOI:
10.1080/14737140.2018.1513792
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center